Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +75

Eli Lilly (LLY) Stock Climbs as China Approves First GLP-1 Weight-Loss Pill

Drug approval Market expansion AI-generated analysis

πŸš€ Eli Lilly stock climbed nearly 3% to a record high after China approved orforglipron (Foundayo) as the nation's first GLP-1 weight-loss pill.

πŸ† Foundayo approval positions Lilly ahead of Novo Nordisk, which is still awaiting clearance for its oral Wegovy in China.

πŸ’Š The new oral therapy offers a once-daily, non-injection alternative that appeals to patients reluctant to use injections.

πŸ“ˆ J.P. Morgan forecasts China's GLP-1 weight-management market could reach $4.5 billion annually within five to seven years.

πŸ‡¨πŸ‡³ China's obese population is projected to top 65% by 2030, creating a massive growth opportunity for Foundayo.

πŸ’° Lilly reported strong third-quarter revenue of $24.4 billion, up 39%, driven by Mounjaro and Zepbound sales.

🌍 Foundayo is already generating $184 million in Q3 revenue globally, with total lifetime revenue reaching $281 million since launch.

βš”οΈ Foundayo will compete against Lilly's own weekly injection as well as injectables from Novo Nordisk, Pfizer, and Innovent Biologics.

πŸ“… More GLP-1 pill competitors are entering the Chinese market, including applications from Jiangsu Hengrui Pharmaceuticals and Huadong Medicine.

Bullish Signals
  • Eli Lilly stock hit a record high in premarket trading after China approved orforglipron (Foundayo) as the country's first GLP-1 weight-loss pill.
  • Foundayo approval places Lilly ahead of competitor Novo Nordisk, which is still waiting for its oral Wegovy to be cleared in China.
  • The new oral therapy addresses patient preferences for non-injection treatments, potentially expanding the addressable market beyond current injectable users.
  • Analyst J.P. Morgan forecasts annual GLP-1 weight-management sales in China could reach $4.5 billion within five to seven years.
  • China's obese population is projected to exceed 65% by 2030, providing a massive growth opportunity for Foundayo.
  • Lilly reported robust third-quarter revenue of $24.4 billion, a 39% increase driven by Mounjaro and Zepbound sales.
  • Foundayo has generated $184 million in Q3 revenue globally, with total lifetime revenue reaching $281 million since its April FDA approval.
Full Analysis
Eli Lilly (LLY) shares surged nearly 3% in premarket trading after China's National Medical Products Administration approved orforglipron, sold as Foundayo, as the country's first GLP-1 weight-loss pill. This regulatory milestone establishes Lilly as a market leader ahead of competitor Novo Nordisk, whose oral Wegovy remains pending approval in China. The approval marks a significant expansion for Lilly into the world's second-largest pharmaceutical market with an oral therapy that addresses patient preferences for non-injection treatments. Foundayo is designed to be taken once daily without food or water restrictions, offering a convenient alternative to injections and potentially expanding the addressable market beyond current injectable users. While Foundayo will compete with Lilly's own weekly GLP-1 injection as well as rival injectables from Novo Nordisk, Pfizer, and Innovent Biologics, the oral format is expected to capture significant demand given that oral therapies already account for roughly one-third of obesity prescriptions in the U.S. Analyst J.P. Morgan forecasts that annual GLP-1 weight-management sales in China could reach 30 billion yuan ($4.5 billion) within five to seven years, driven by a growing obese population projected to exceed 65% by 2030. Lilly's broader financial performance remains robust, with total third-quarter revenue rising 39% to $24.4 billion, primarily driven by Mounjaro and Zepbound sales. The company has not yet disclosed specific pricing or launch timelines for Foundayo in China, though early availability on JD.com suggests imminent market entry.